What’s the current market cap for Royalty Pharma stock?

Royalty Pharma (RPRX) has a market cap of $24bn as of June 15, 2026.

What is the P/E ratio for Royalty Pharma stock?

The price to earnings (P/E) ratio for Royalty Pharma (RPRX) stock is 26.87 as of June 15, 2026.

Does Royalty Pharma stock pay dividends?

Yes, the Royalty Pharma (RPRX) stock pays dividends to shareholders. As of June 15, 2026, the dividend rate is $0.91 and the yield is 1.71%. Royalty Pharma has a payout ratio of 46.88% on a trailing twelve-month basis.

When is the next Royalty Pharma dividend payment date?

The next Royalty Pharma (RPRX) dividend payment date is unconfirmed.

What is the beta indicator for Royalty Pharma?

Royalty Pharma (RPRX) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Royalty Pharma stock | $RPRX Share Price

13:30

09:10

04:45

00:25

20:00

About Royalty Pharma

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Ticker

$RPRX

Sector

Health

Primary listing

NASDAQ

Employees

100

Headquarters

New York, United States

Website

www.royaltypharma.com

Royalty Pharma Metrics

BasicAdvanced

$24bn

26.87

$2.04

0.40

$0.91

1.71%

What the Analysts think about Royalty Pharma

Analyst ratings (Buy, Hold, Sell) for Royalty Pharma stock.

Bulls say / Bears say

Upgraded full-year 2026 Portfolio Receipts guidance to $3.325–$3.45 billion from $3.275–$3.425 billion, indicating management’s confidence in ongoing royalty income growth.

Royalty Receipts rose 13% to $887 million and Portfolio Receipts climbed 10% to $925 million in Q1 2026, showing strong revenue momentum.

Repurchased 1 million shares for $50 million and increased the quarterly dividend by 7%, underlining a shareholder-focused capital allocation approach.

As of March 31, 2026, cash and cash equivalents were $586 million compared to total debt of $9.2 billion, highlighting significant leverage and potential refinancing risk.

A $69 million non-cash impairment was recorded for Tazverik in Q1 2026, reflecting execution risk and the chance of future write-downs in the royalty portfolio.

The top three products—Vertex’s cystic fibrosis franchise, GSK’s Trelegy, and Roche’s Evrysdi—made up about 47% of Q1 2026 Portfolio Receipts, leading to revenue concentration and greater exposure to the individual performance of these products.

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.

Royalty Pharma Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Royalty Pharma Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RPRX

Capital at risk

Market open

Upcoming events

No upcoming events